| Theme |
Updates on hemodialysis technologies |
| Title |
Extracorporeal albumin dialysis (ECAD) |
| Author |
Takaya Abe |
Kidney Center & Department Urology |
| Author |
Nariyuki Sasaki |
Dialysis Center Seitetsu Memorial Hospital |
| Author |
Toru Maruyama |
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University |
| [ Summary ] |
Using high flux membranes, small molecular weight albumin binding uremic toxins (ABT) which are strongly bound to albumin are not adequately removed by conventional dialysis techniques. Accumulations of ABT cause adverse effects directly and indirectly. Albumin has the ability to bind with multiple molecules (because of ligand binding properties). One type of blood purification therapy in which ligand binding properties are applied is that employing adsorption, known as 'extracorporeal albumin dialysis (ECAD)'. ECAD can remove ABT more efficiently and selectively than conventional dialysis techniques. In the future, it will be necessary to establish simple, real time ABT measuring techniques and to conduct large-scale ABT studies. |